Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesEXACT Sciences Corporation

EXACT Sciences Corporation

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-04-23T21:04:23.732070Z
Market Cap
20026.08M

Momentum Score

…

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
38.81
Low
104.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
3246.99M
Revenue Per Share
17.21
Gross Profit TTM
2262.84M
Debt / Equity
1.05
ROE
-8.66%
Net Debt
1566.70M
ROCE
-1.90%
Diluted EPS TTM
-1.10

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -203.89M -1036.16M -201.75M -632.57M -842.51M
Net income -207.95M -1028.86M -204.15M -623.51M -595.62M
Selling general administrative 888.67M 1420.60M 1394.60M 737.30M 801.26M
Selling and marketing expenses 1050.18M 247.50M 225.70M 846.01M 861.89M
Gross profit 2262.84M 1918.67M 1762.17M 1509.88M 1308.33M
Reconciled depreciation 221.58M 214.86M 206.61M 197.56M 180.35M
Ebit -99.08M -1004.19M -177.32M -577.54M -835.47M
Ebitda 122.50M -789.33M 29.28M -480.09M -740.47M
Depreciation and amortization 221.58M 214.86M 206.61M 97.45M 95.00M
Non operating income net other - - - -19.43M 31.78M
Operating income -99.08M -1048.70M -215.01M -577.54M -835.47M
Other operating expenses 3346.07M 3807.57M 2714.78M 2661.82M 2602.55M
Interest expense 32.87M 31.97M 24.42M 19.63M 18.61M
Tax provision 4.06M -7.30M 2.40M -9.06M -246.88M
Net interest income -39.36M -37.27M -29.77M -19.63M -18.61M
Non recurring - - - 15.97M 20.21M
Income tax expense 4.06M -7.30M 2.40M -9.06M -246.88M
Total revenue 3246.99M 2758.87M 2499.77M 2084.28M 1767.09M
Total operating expenses 2361.92M 2967.37M 1977.18M 2087.43M 2143.80M
Cost of revenue 984.15M 840.20M 737.60M 574.39M 458.76M
Total other income expense net -104.81M 12.54M 13.27M -55.03M -7.04M
Net income from continuing ops -207.95M -1028.86M -204.15M -623.51M -595.62M
Net income applicable to common shares - - - -623.51M -595.62M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5860.63M 5928.14M 6471.33M 6226.87M 6684.88M
Intangible assets 919.92M 1009.69M 1890.40M 1956.24M 2094.41M
Other current assets 126.28M 122.05M 85.63M 73.90M 74.12M
Total liab 3459.58M 3525.89M 3326.03M 3183.71M 3297.25M
Total stockholder equity 2401.05M 2402.25M 3145.30M 3043.16M 3387.64M
Other current liab 425.99M 366.06M 14.82M 309.46M 30.97M
Common stock 1.91M 1.86M 1.81M 1.78M 1.74M
Capital stock 1.91M 1.86M 1.81M 1.78M 1.74M
Retained earnings -4705.98M -4498.03M -3469.18M -3265.03M -2641.52M
Other liab - - - 345.06M 417.78M
Good will 2368.05M 2366.68M 2367.12M 2346.04M 2335.17M
Other assets - - - 36.68M 74.59M
Cash 956.00M 600.89M 605.38M 242.49M 315.47M
Total current liabilities 641.15M 732.19M 514.70M 412.75M 517.07M
Current deferred revenue - - 341.68M - 398.56M
Net debt 1566.70M 2153.87M 1949.35M 2204.38M 2046.93M
Short term debt 39.29M 276.56M 79.38M 28.37M 19.71M
Short long term debt - 249.15M 50.00M - -
Short long term debt total 2522.70M 2754.76M 2554.72M 2446.87M 2362.40M
Other stockholder equity 7102.77M 6899.37M 6611.24M 6311.64M 6028.86M
Property plant equipment - - - 684.76M 754.47M
Total current assets 1555.85M 1571.42M 1194.37M 982.26M 1426.24M
Net tangible assets - - - 697.12M -1041.95M
Short term investments 8.71M 437.14M 172.27M 389.56M 715.00M
Net receivables 298.65M 248.97M 203.62M 158.04M 216.65M
Long term debt 2327.18M 2321.07M 2314.28M 2186.11M 2180.23M
Inventory 166.20M 162.38M 127.47M 118.26M 104.99M
Accounts payable 175.87M 89.57M 78.82M 74.92M 67.83M
Accumulated other comprehensive income 2.36M -0.94M 1.43M -5.24M -1.44M
Common stock total equity - - - 1.78M 1.74M
Retained earnings total equity - - - -3265.03M -2641.52M
Non currrent assets other 185.81M 169.72M -287.55M 90.58M 74.59M
Non current assets total 4304.78M 4356.72M 5276.97M 5244.62M 5258.65M
Capital lease obligations 195.52M 184.54M 190.45M 210.76M 201.88M
Long term debt total - - - 2186.11M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 376.51M -442.15M 49.68M 278.76M -387.77M
Change to liabilities - - - -52.18M 169.80M
Total cashflows from investing activities 195.12M -442.15M - 74.07M -1082.09M
Net borrowings -249.17M 216.75M - 50.00M -23.75M
Total cash from financing activities -338.09M 231.87M 159.77M 76.48M 8.47M
Change to operating activities - - - -22.05M -74.62M
Net income -207.95M -1028.86M -204.15M -623.51M -595.62M
Change in cash 349.36M -3.04M 366.88M -72.98M -1175.83M
Begin period cash flow 606.64M 609.67M 242.79M 315.77M 1491.59M
End period cash flow 956.00M 606.64M 609.67M 242.79M 315.77M
Total cash from operating activities 491.44M 210.54M 156.12M -223.56M -102.24M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 221.58M 214.86M 206.61M 197.56M 180.35M
Other cashflows from investing activities 28.27M -0.23M - 9.77M -0.74M
Dividends paid - - 169.52M - 37.51M
Change to inventory -3.77M -34.91M -7.69M -13.23M -9.22M
Change to account receivables -48.89M -46.26M -43.42M 61.09M 25.15M
Sale purchase of stock 26.54M 31.23M 28.34M 25.49M 23.07M
Other cashflows from financing activities -117.36M -17.75M 21.79M 44.47M 9.15M
Change to netincome - - - 181.28M 195.25M
Capital expenditures 134.66M 135.99M 124.19M 214.46M 135.77M
Change receivables - - - 61.09M 25.15M
Cash flows other operating - - - 118.41M -129.55M
Cash and cash equivalents changes - - - -73.01M -1175.85M
Change in working capital 121.83M -56.01M -0.34M -26.38M 111.11M
Stock based compensation 217.67M 214.88M 231.31M 206.82M 253.06M
Other non cash items 139.86M 875.78M -76.36M 33.84M 202.04M
Free cash flow 356.78M 74.55M 31.93M -438.02M -238.00M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TMO
Thermo Fisher Scientific Inc		 -15.12
2.11%		 702.59 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -1.34
0.57%		 233.97 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 24.91 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.17
0.68%		 24.93 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

EXACT Sciences Corporation

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

5505 Endeavor Lane, Madison, WI, United States, 53719

608 284 5700

https://www.exactsciences.com

7100

Name Title Year Born
Mr. Kevin T. Conroy Chairman of The Board & CEO 1966
Mr. Jeffrey T. Elliott CFA Exec. VP, CFO & COO 1978
Mr. D. Scott Coward Chief Legal Officer 1965
Mr. Graham P. Lidgard Emeritus Chief Science Officer 1949
Mr. Everett V. Cunningham Chief Commercial Officer 1966
Dr. Jorge A. Garces Ph.D. Chief Science Officer 1972
Mr. Sri Kalluri Chief Information Officer NA
Ms. Megan Jones Associate Mang. of Investor Relations NA
Mr. Tim Caprez Chief Compliance Counsel & VP NA
Mr. Vic Parker Head of Sales NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…